DentalKart disowns its own revenue guidance and brand-mix target
CEO Vikas Agarwal retracted the INR 500-600 cr FY27 target and the 70% own-brand share goal, calling both products of past immaturity.
What's new
- FY26 total income was INR 283 cr; management disowned its INR 500-600 cr FY27 target from 2023.
- Own-brand stock-outs peaked at 33% in H2FY26; now 14.6%, with a 5-7% target.
- Q4 gross margin compressed to 23.7% from ~34% due to own-brand unavailability.
- The 70% own-brand share aspiration was dropped in favor of a 45-50% cap.
Themes from the call
Guidance
Management retracted its INR 500-600 cr revenue target and now guides for a 'North Star' of tripling revenue over 3-4 years, or roughly 45% CAGR, with no specific near-term number.
Margins
Q4 gross margin fell to 23.7% from ~34% as own-brand stock-outs forced a shift to lower-margin MNC products; recovery to 30%+ in FY27 depends on restocking.
Supply Chain
Own-brand stock-out rate is down to 14.6% from a peak of 33% but still above the 5-7% target, with 8-12 week regulatory lead times constraining recovery.
Guidance watch
- INR 500-600 cr FY27 revenue target retracted; new guidance is tripling revenue over 3-4 years, or roughly 45% CAGR.
- EBITDA margin target of mid-teens in 3-4 years, contingent on own-brand availability.
- SmileWorks prosthetics unit targeted to reach INR 10-12 cr by end-FY27 from INR 4.8 cr.
Risk flags
- A strategic pivot on own-brand mix from 70% to 45-50% changes the margin recovery thesis and may cap profitability.
- Tier 3-4 delivery remains at five days, missing a two-year-old target, while quick commerce is raising consumer expectations.
- The CEO's closing admission that 'last year was not as I promised' acknowledges a credibility gap.
Key quotes
-
"Earlier calls or guidance showed our immaturity in handling capital markets. ... I do not want to provide specific guidance."
— Dr. Vikas Agarwal, CEO -
"Last year was not as I promised, but I want to assure you it was a one-off caused by our mistakes, not a lack of demand."
— Dr. Vikas Agarwal, CEO
The brief
DentalKart's June 2026 earnings call was an exercise in disowning promises. CEO Vikas Agarwal retracted the INR 500-600 cr revenue target set in late 2023, labeling it a sign of immaturity. He also abandoned the 70% own-brand sales mix goal, capping it at 45-50% to protect platform neutrality. The reasons are concrete. Own-brand stock-outs peaked at 33% in H2FY26, compressing Q4 gross margins to 23.7% from ~34%. That stock-out forced a shift to lower-margin MNC products, eroding the very profitability the own-brand push was meant to deliver.
The operational damage is clear. A target to get national delivery under three days has been missed. Tier 3-4 delivery is still at five days. Revenue per order fell to INR 3,670 from INR 4,600 after discontinuing a higher-value offline trading business. The core marketplace grew 33%, adding 70,000 dentists, but that growth came with thinner economics.
The new guidance is intentionally vague: a North Star of tripling revenue over 3-4 years, or roughly 45% CAGR, with mid-teens EBITDA margin in 3-4 years. That is a long way from the original three-year INR 600 cr promise. The SmileWorks prosthetics unit is growing, targeting INR 10-12 cr by FY27, but it's still small.
Agarwal's closing remarks were candid: 'Last year was not as I promised.' The company is now in a reset phase, prioritizing customer service and faster delivery over aggressive own-brand scaling. The credibility cost of that reset is real. Investors got a new timeline and a lower, more honest ambition. Whether that's enough depends on execution, not promises.
DentalKart is now selling honesty where it once sold a 3-year plan. The open question is whether that's enough.